...
首页> 外文期刊>Ophthalmic plastic and reconstructive surgery >Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients.
【24h】

Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients.

机译:透明质酸透明质酸凝胶(Restylane)填充剂:从美国眼科整形外科学会会员疗法中汲取的经验教训,治疗286例患者。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To review injection techniques and patient satisfaction with injection of Restylane in various facial areas by American Society of Ophthalmic Plastic and Reconstructive Surgery members. METHODS: Data from 286 patients treated with Restylane in nine American Society of Ophthalmic Plastic and Reconstructive Surgery practices were abstracted to a spreadsheet for analysis. RESULTS: Nine practices performed Restylane injections for 8.8 months on average (range, 2 to 28 months). Average practice volume per patient was 1.2 ml (range, 0.7 to 2.1 ml). Nine of nine practices injected the nasolabial and melolabial folds, 9 of 9 practices injected the lips, and 6 of 9 injected the glabella. Only 2 of 9 practices injected other fillers concurrently. Botox was injected concurrently by 8 of 9 practices. On a scale of 1 to 10, physicians rated average patient discomfort during Restylane injection 4.6 with topical anesthesia and 2.1 with injectable lidocaine, with or without topical anesthesia. The end point for injection was determined by visual cues, volume of injection, extrusion of the product, and palpation. "Problematic" complications, including bruising, swelling, bumpiness, and redness each had an incidence of 5% or less. Patient satisfaction on a scale of 1 to 10 had an average rating of 8.1, compared with that of Botox injection (8.9), upper blepharoplasty (8.9), and collagen injection (6.6). The source of Restylane patients was estimated to be existing Botox patients (45%); existing non-Botox patients (18%); word of mouth (14%); and new patients for other services (13%). CONCLUSIONS: Injection techniques, volume, end points, and anesthesia vary for different facial areas and between practices. Patients experience mild to moderate injection discomfort that is lessened with injectable lidocaine. Self-limited problems occur in about 5% of patients. Physician-determined patient satisfaction is perceived to be higher than that of collagen injection but slightly lower than that of botulinum toxin injection. The major source of Restylane patients was from existing practice patients, especially botulinum toxin patients.
机译:目的:回顾美国眼科整形与重建外科学会会员在各种面部区域注射瑞斯汀的注射技术和患者满意度。方法:将来自9个美国眼科整形与重建手术协会的286例接受Restylane治疗的患者的数据提取到电子表格中进行分析。结果:九个实践平均进行了8.8个月(范围2至28个月)的瑞斯汀注射。每位患者的平均练习量为1.2毫升(范围为0.7到2.1毫升)。 9种方法中有9种注入了鼻唇沟和半唇折痕,9种方法中有9种注入了嘴唇,9种方法中有6种注入了唇label。 9种做法中只有2种同时注入其他填充剂。 9种做法中有8种同时注射了肉毒杆菌毒素。在1到10的量表中,医生在进行局部麻醉或不进行局部麻醉的瑞斯丁烷注射期间,平均患者不适感为4.6,局部麻醉为2.1,注射利多卡因。通过视觉提示,注射量,产品挤出和触诊确定注射终点。包括瘀伤,肿胀,bump肿和发红在内的“问题性”并发症的发生率均在5%或以下。与肉毒杆菌注射(8.9),上睑成形术(8.9)和胶原蛋白注射(6.6)相比,患者满意度在1至10的平均评分为8.1。 Restylane患者的来源估计是现有的肉毒杆菌毒素患者(45%)。现有的非肉毒杆菌毒素患者(18%);口碑(14%);以及其他需要其他服务的患者(13%)。结论:注射技术,容量,终点和麻醉因面部区域和实践而异。患者会出现轻度至中度的注射不适感,可注射利多卡因可减轻这种不适感。自我约束的问题约有5%的患者发生。医师确定的患者满意度被认为高于胶原蛋白注射剂的满意度,但略低于肉毒杆菌毒素注射剂的满意度。 Restylane患者的主要来源是现有的执业患者,尤其是肉毒杆菌毒素患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号